Source comparison
Tesamorelin + Ipamorelin Blend Science Explained: Research Protocol Comparison
The table below compares single-peptide protocols against the dual-pathway blend across key pharmacodynamic and practical research parameters: Tesamorelin Monotherapy (1–2 mg) 4.2–6.8× baseline 90–120 +18–22% None Moderate (somatostatin rebound) Effective for
This comparison does not assign a generated winner or score.
- The table below compares single-peptide protocols against the dual-pathway blend across key pharmacodynamic and practical research parameters:
- Tesamorelin Monotherapy (1–2 mg)
- 4.2–6.8× baseline
- 90–120
- +18–22%
- None
- Moderate (somatostatin rebound)
- Effective for single-pulse GH research; limited by negative feedback after initial release. Best for circadian-timed protocols.
- Ipamorelin Monotherapy (200–300 mcg)
- 3.1–4.5× baseline
- 60–90
- +12–16%
- None (highly selective)
- Low (minimal tachyphylaxis)
- Excellent safety profile but lower peak GH vs GHRH analogs. Ideal for chronic dosing studies without HPA axis interference.
- Tesamorelin + Ipamorelin Blend (1 mg + 200 mcg)
- 6.9–9.2× baseline
- 180–240
- +28–34%
- Very Low (dual-pathway prevents single-receptor saturation)
- Synergistic GH output with extended pulse duration. Mimics physiological pulsatility better than either monotherapy. Optimal for metabolic and body composition research models.
- Exogenous rhGH Infusion (matched total GH dose)
- Sustained 2.5–3× baseline
- Continuous (6–8 hours)
- +22–26%
- N/A
- N/A (receptor agonist, not secretagogue)
- Higher total GH exposure but metabolically distinct from pulsatile release. Associated with insulin resistance in chronic models. Not equivalent to secretagogue protocols.